FDA has certified Lantheus Holdings' DEFINITY manufacturing facility to improve the efficacy of ultrasound diagnostics for patients with abnormal echocardiograms. The 16,000-square-foot facility is located in Massachusetts. The plant's capacity covers the company's current drug production needs with reserve.